08037.HK
China Biotech Services Holdings Limited
HKSE · Healthcare · Medical - Diagnostics & Research · HK
HKD 0.63
+3.28%Year over year
Reported trailing growth
- Revenue
- +23.8%
- EBITDA
- +35.2%
- EBIT
- -11.2%
- EPS
- +80.3%
- Free cash flow
- —
- Operating cash flow
- +47.7%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -65.9%
- EBITDA
- +41.0%
- EBIT
- +46.9%
- Net income
- +65.3%
- EPS
- +64.8%
- Free cash flow
- +3.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026